Akèy › Kansè Endomèt › Michigan › Grand Rapids
Etid klinik pou Kansè Endomèt nan Grand Rapids, MI
18 etid pou Kansè Endomèt ap chèche patisipan nan sit nan ak bò kote Grand Rapids (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Ap rekriteFaz 3
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids
- Trinity Health Grand Rapids Hospital, Grand Rapids
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Ap rekriteFaz 2
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids
- Trinity Health Grand Rapids Hospital, Grand Rapids
A Study of PHST001 in Advanced Solid Tumors
Ap rekriteFaz 1
- START Center for Cancer Research - Midwest, Grand Rapids
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- South Texas Accelerated Research Therapeutics (START), Grand Rapids
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- BAMF Health, Grand Rapids
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Ap rekriteFaz 2
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Ap rekriteFaz 2
- Research Site, Grand Rapids
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Ap rekriteFaz 1
- BAMF Health Inc., Grand Rapids
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Ap rekriteFaz 1/2
- START Midwest, Grand Rapids
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Ap rekriteEtid obsèvasyon
- Cancer & Hematology Centers of Western Michigan, Grand Rapids
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Ap rekriteFaz 3
- Corewell Health, Grand Rapids
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Ap rekriteFaz 1
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
A Study of MGC026 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- START Midwest, Grand Rapids
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- START - Midwest, Grand Rapids
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Ap rekriteFaz 1/2
- START Midwest, Grand Rapids
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- START Midwest, Grand Rapids
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
Ap rekriteFaz 2
- START Midwest, Grand Rapids
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Ap rekriteFaz 1/2
- START Midwest, Grand Rapids
Etid Kansè Endomèt nan lòt vil
- Houston, TX68 etid
- New York City, NY52 etid
- Boston, MA50 etid
- Arlington, VA39 etid
- Nashville, TN38 etid
- Los Angeles, CA34 etid
- St. Louis, MO29 etid
- Philadelphia, PA28 etid
- San Antonio, TX27 etid
- Columbus, OH25 etid
- Oklahoma City, OK25 etid
- Chicago, IL25 etid
Lòt etid nan Grand Rapids
- Kansè Poumon ki pa ti selil44 etid
- Kansè kolorektal40 etid
- Kansè (tout kalite)28 etid
- Kansè nan tete26 etid
- Kansè ovè24 etid
- Kansè Metastatik22 etid
- Kansè pwostat19 etid
- Kansè lestomak18 etid
- Kansè pankreyas18 etid
- Melanom17 etid
- Karsinòm selil skuamèz tèt ak kou15 etid
- Kansè tete negatif triple15 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.